繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 肿瘤 >> 肺癌 >> 药品推荐 >> 雷莫芦单抗注射剂|CYRAMZA (ramucirumab) injection,

雷莫芦单抗注射剂|CYRAMZA (ramucirumab) injection,

2015-01-16 08:16:36  作者:新特药房  来源:互联网  浏览次数:361  文字大小:【】【】【
简介: ——美国FDA扩展Cyramza的批准使用治疗侵袭性非小细胞肺癌2014年12月12日,美国FDA批准Cyramza (ramucirumab)治疗转移性非小细胞癌(NSCLC)新适应症。NSCLC是最常见形式的肺癌,当癌细胞在肺部组织形成时 ...

——美国FDA扩展Cyramza的批准使用治疗侵袭性非小细胞肺癌
2014年12月12日,美国FDA批准Cyramza (ramucirumab)治疗转移性非小细胞癌(NSCLC)新适应症。NSCLC是最常见形式的肺癌,当癌细胞在肺部组织形成时就会发生这种疾病。美国国家癌症研究所预测,2014年将有22.421万美国人被确诊患有肺癌,有15.926万人将死于这种疾病。
Cyramza通过阻断帮助肿瘤增长的血液供应而发挥作用。这款药物适用于以铂类为基础化疗治疗期间或治疗后肿瘤出现恶化的患者,它将与另一款化疗药物多西他赛合并用药。
“今天的批准是Cyramza在2014年获得的第三项适应症,”FDA药物评价与研究中心血液及肿瘤产品办公室主任、医学博士Pazdur称。“研究Cyramza用于各种恶化肿瘤的努力为患者提供了重要的治疗选择。”
4月21日,FDA批准Cyramza作为一种单一制剂用于治疗晚期胃癌或胃食管连接部腺癌,后者是位于食管与胃连接处的癌症。11月5日,FDA批准Cyramza与另一款化疗药物紫杉醇合并用于晚期胃或GEJ腺癌。
Cyramza加多西多赛用于转移性NSCLC的获批基于一项由1253名先前有过治疗并恶化肺癌患者参与的临床研究。研究受试者被随机配给Cyramza+多西多赛或安慰剂+多西多赛。当疾病出现恶化或发生无法耐受副作用时停止治疗。
这项试验旨在检测总生存期,即受试者死亡前的存活时间。结果显示,Cyramza+多西多赛治疗受试者中有一半的人从治疗开始存活了10.5个月,相比之下,安慰剂+多西多赛治疗受试者中一半的人从治疗开始存活了9.1个月。
临床研究中观察到的与Cyramza+多西多赛相关的最常见副作用包括抗感染的白细胞水平下降(嗜中性白血球减少)、疲劳及口腔炎症。Cyramza可引起严重出血、血栓、血压升高及可能损伤创面愈合。
批准日期:2014年12月20日:公司:礼来公司
注射用CYRAMZA(雷莫芦单抗,ramucirumab)为静脉输注治疗非小细胞肺癌和晚期胃癌
美国初次批准:2014
适应证和用途
CYRAMZA®是一个人血管内皮升长因子受体2拮抗剂适用:
⑴ 作为单药或与紫杉醇联用,为晚期胃或胃-食道连接腺癌,有用或氟嘧啶[fluoropyrimidine]-或含铂化疗后疾病进展的治疗。
⑵ 与多烯紫杉醇联用,为治疗转移非小细胞肺癌用或基于铂化疗后疾病进展。有EGFR或ALK基因组肿瘤畸变患者用FDA-批准的治疗对这些畸变接受CYRAMZA治疗以前应有疾病进展。
剂量和给药方法
只为静脉输注。不要静脉推注或丸注给药。
胃癌
⑴ CYRAMZA的推荐剂量或作为单药或与每周紫杉醇联用是8 mg/kg每2周。
非小细胞肺癌
⑵ 在输注多烯紫杉醇前,在21天疗程在第1天静脉给予CYRAMZA 10 mg/kg。
剂型和规格
注射:
⑴ 单剂量小瓶,100 mg/10 mL(10 mg每mL)溶液(3)
⑵ 单剂量小瓶,500 mg/50 mL(10 mg每mL)溶液(3)


HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use CYRAMZA safely and effectively. See full prescribing information for CYRAMZA.
CYRAMZA (ramucirumab) injection, for intravenous use
Initial U.S. Approval: 2014
WARNING: HEMORRHAGE See full prescribing information for complete boxed warning.
CYRAMZA increased the risk of hemorrhage, including severe and sometimes fatal hemorrhagic events. Permanently discontinue CYRAMZA in patients who experience severe bleeding [see Dosage and Administration (2.3), Warnings and Precautions (5.1)].
RECENT MAJOR CHANGES

Indications and Usage
         Gastric Cancer (1.1) 11/2014
         Non-Small Cell Lung Cancer (1.2) 12/2014
Dosage and Administration:
         Recommended Dose and Schedule (2.1) 12/2014
         Dose Modifications (2.3) 12/2014
Warnings and Precautions:
         Hemorrhage (5.1) 12/2014
         Hypertension (5.3) 12/2014
         Gastrointestinal Perforations (5.5) 12/2014
INDICATIONS AND USAGE
CYRAMZA® is a human vascular endothelial growth factor receptor 2 antagonist indicated
as a single agent or in combination with paclitaxel, for treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. (1.1)
in combination with docetaxel, for treatment of metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. (1.2)
DOSAGE AND ADMINISTRATION
For intravenous infusion only. Do not administer as an intravenous push or bolus. (2)
Gastric Cancer
The recommended dose of CYRAMZA either as a single agent or in combination with weekly paclitaxel is 8 mg/kg every 2 weeks. (2.1, 2.2, 2.3)
Non-Small Cell Lung Cancer
Administer CYRAMZA at 10 mg/kg intravenously on day 1 of a 21-day cycle prior to docetaxel infusion. (2.1, 2.2, 2.3)
DOSAGE FORMS AND STRENGTHS
Injection:
100 mg/10 mL (10 mg per mL) solution, single-dose vial (3)
500 mg/50 mL (10 mg per mL) solution, single-dose vial (3)
CONTRAINDICATIONS
None (4)
WARNINGS AND PRECAUTIONS
Arterial Thromboembolic Events (ATEs): Serious, sometimes fatal ATEs have been reported in clinical trials. Discontinue CYRAMZA for severe ATEs. (5.2)
Hypertension: Monitor blood pressure and treat hypertension. Temporarily suspend CYRAMZA for severe hypertension. Discontinue CYRAMZA for hypertension that cannot be medically controlled. (5.3)
Infusion-Related Reactions: Monitor for signs and symptoms during infusion. (5.4)
Gastrointestinal Perforation: Discontinue CYRAMZA. (5.5)
Impaired Wound Healing: Withhold CYRAMZA prior to surgery. (5.6)
Clinical Deterioration in Patients with Cirrhosis: New onset or worsening encephalopathy, ascites, or hepatorenal syndrome can occur in patients with Child-Pugh B or C cirrhosis. (5.7)
Reversible Posterior Leukoencephalopathy Syndrome: Discontinue CYRAMZA. (5.8)
ADVERSE REACTIONS
The most common adverse reactions observed in single-agent CYRAMZA-treated patients at a rate of ≥10% and ≥2% higher than placebo were hypertension and diarrhea. (6.1)
The most common adverse reactions observed in patients treated with CYRAMZA plus paclitaxel at a rate of ≥30% and ≥2% higher than placebo plus paclitaxel were fatigue, neutropenia, diarrhea, and epistaxis. (6.1)
The most common adverse reactions observed in patients treated with CYRAMZA plus docetaxel at a rate of ≥30% and ≥2% higher than placebo plus docetaxel were neutropenia, fatigue/asthenia, and stomatitis/mucosal inflammation. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS
Pregnancy: Based on its mechanism of action, CYRAMZA may cause fetal harm. (8.1)
Nursing Mothers: Discontinue nursing or discontinue CYRAMZA. (8.3)
See 17 for PATIENT COUNSELING INFORMATION.
Revised: 12/2014
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
1.1 Gastric Cancer
CYRAMZA® as a single agent, or in combination with paclitaxel, is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
1.2 Non-Small Cell Lung CancerCYRAMZA, in combination with docetaxel, is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy.
Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. 
2 DOSAGE AND ADMINISTRATION
Do not administer CYRAMZA as an intravenous push or bolus.
2.1 Recommended Dose and Schedule
Gastric Cancer
The recommended dose of CYRAMZA either as a single agent or in combination with weekly paclitaxel is 8 mg/kg every 2 weeks administered as an intravenous infusion over 60 minutes. Continue CYRAMZA until disease progression or unacceptable toxicity.
When given in combination, administer CYRAMZA prior to administration of paclitaxel.
Non-Small Cell Lung Cancer
The recommended dose of CYRAMZA is 10 mg/kg administered by intravenous infusion over approximately 60 minutes on day 1 of a 21-day cycle prior to docetaxel infusion. Continue CYRAMZA until disease progression or unacceptable toxicity.
2.2 Premedication
Prior to each CYRAMZA infusion, premedicate all patients with an intravenous histamine H1 antagonist (e.g., diphenhydramine hydrochloride).
For patients who have experienced a Grade 1 or 2 infusion-related reaction, also premedicate with dexamethasone (or equivalent) and acetaminophen prior to each CYRAMZA infusion [see Dosage and Administration (2.3)].
2.3 Dose Modifications
Infusion-Related Reactions (IRR)
Reduce the infusion rate of CYRAMZA by 50% for Grade 1 or 2 IRRs.
Permanently discontinue CYRAMZA for Grade 3 or 4 IRRs [see Dosage and Administration (2.2) and Warnings and Precautions (5.4)].
Hypertension
Interrupt CYRAMZA for severe hypertension until controlled with medical management.
Permanently discontinue CYRAMZA for severe hypertension that cannot be controlled with antihypertensive therapy [see Warnings and Precautions (5.3)].
Proteinuria
Interrupt CYRAMZA for urine protein levels ≥2 g/24 hours. Reinitiate treatment at a reduced dose (see Table 1) once the urine protein level returns to <2 g/24 hours. If the protein level ≥2 g/24 hours reoccurs, interrupt CYRAMZA and reduce the dose (see Table 1) once the urine protein level returns to <2 g/24 hours.
Permanently discontinue CYRAMZA for urine protein level >3 g/24 hours or in the setting of nephrotic syndrome [see Adverse Reactions (6.1)].
Table 1: CYRAMZA Dose Reductions for Proteinuria 

Initial CYRAMZA Dose First Dose Reduction to: Second Dose Reduction to:
8 mg/kg 6 mg/kg 5 mg/kg
10 mg/kg 8 mg/kg 6 mg/kg
Wound Healing Complications
Interrupt CYRAMZA prior to scheduled surgery until the wound is fully healed [see Warnings and Precautions (5.6)].
Arterial Thromboembolic Events, Gastrointestinal Perforation, or Grade 3 or 4 Bleeding
Permanently discontinue CYRAMZA [see Warnings and Precautions (5.1, 5.2, 5.5)].
For toxicities related to paclitaxel or docetaxel, refer to the current prescribing information.
2.4 Preparation for Administration
Inspect vial contents for particulate matter and discoloration prior to dilution [see Description (11)]. Discard the vial, if particulate matter or discolorations are identified. Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) until time of use. Keep the vial in the outer carton in order to protect from light.
Calculate the dose and the required volume of CYRAMZA needed to prepare the infusion solution. Vials contain either 100 mg/10 mL or 500 mg/50 mL at a concentration of 10 mg/mL solution of CYRAMZA.
Withdraw the required volume of CYRAMZA and further dilute with only 0.9% Sodium Chloride Injection in an intravenous infusion container to a final volume of 250 mL. Do not use dextrose containing solutions.
Gently invert the container to ensure adequate mixing.
DO NOT FREEZE OR SHAKE the infusion solution. DO NOT dilute with other solutions or co-infuse with other electrolytes or medications.
Store diluted infusion for no more than 24 hours at 2°C to 8°C (36°F to 46°F) or 4 hours at room temperature (below 25°C [77°F]).
Discard vial with any unused portion of CYRAMZA.
2.5 Administration
Visually inspect the diluted solution for particulate matter and discoloration prior to administration. If particulate matter or discolorations are identified, discard the solution.
Administer diluted CYRAMZA infusion via infusion pump over 60 minutes through a separate infusion line. Use of a protein sparing 0.22 micron filter is recommended. Flush the line with sterile sodium chloride (0.9%) solution for injection at the end of the infusion.
3 DOSAGE FORMS AND STRENGTHS
Injection:
100 mg/10 mL (10 mg per mL) solution, single-dose vial
500 mg/50 mL (10 mg per mL) solution, single-dose vial
Close
4 CONTRAINDICATIONS
None
5 WARNINGS AND PRECAUTIONS
5.1 Hemorrhage
CYRAMZA increased the risk of hemorrhage and gastrointestinal hemorrhage, including severe and sometimes fatal hemorrhagic events. In Study 1, the incidence of severe bleeding was 3.4% for CYRAMZA and 2.6% for placebo. In Study 2, the incidence of severe bleeding was 4.3% for CYRAMZA plus paclitaxel and 2.4% for placebo plus paclitaxel.
Patients with gastric cancer receiving nonsteroidal anti-inflammatory drugs (NSAIDs) were excluded from enrollment in Studies 1 and 2; therefore, the risk of gastric hemorrhage in CYRAMZA-treated patients with gastric tumors receiving NSAIDs is unknown. Permanently discontinue CYRAMZA in patients who experience severe bleeding [see Dosage and Administration (2.3)].
In Study 3, the incidence of severe bleeding was 2.4% for CYRAMZA plus docetaxel and 2.3% for placebo plus docetaxel. Patients with NSCLC receiving therapeutic anticoagulation or chronic therapy with NSAIDS or other anti-platelet therapy other than once daily aspirin or with radiographic evidence of major airway or blood vessel invasion or intratumor cavitation were excluded from Study 3; therefore the risk of pulmonary hemorrhage in these groups of patients is unknown.
5.2 Arterial Thromboembolic Events
Serious, sometimes fatal, arterial thromboembolic events (ATEs) including myocardial infarction, cardiac arrest, cerebrovascular accident, and cerebral ischemia occurred in clinical trials including 1.7% of 236 patients who received CYRAMZA as a single agent for gastric cancer in Study 1. Permanently discontinue CYRAMZA in patients who experience a severe ATE [see Dosage and Administration (2.3)].
5.3 Hypertension
An increased incidence of severe hypertension occurred in patients receiving CYRAMZA as a single agent (8%) as compared to placebo (3%) and in patients receiving CYRAMZA plus paclitaxel (15%) as compared to placebo plus paclitaxel (3%) and in patients receiving CYRAMZA plus docetaxel (6%) as compared to placebo plus docetaxel (2%).
Control hypertension prior to initiating treatment with CYRAMZA. Monitor blood pressure every two weeks or more frequently as indicated during treatment.
Temporarily suspend CYRAMZA for severe hypertension until medically controlled. Permanently discontinue CYRAMZA if medically significant hypertension cannot be controlled with antihypertensive therapy or in patients with hypertensive crisis or hypertensive encephalopathy [see Dosage and Administration (2.3)].
5.4 Infusion-Related Reactions
Prior to the institution of premedication recommendations across clinical trials of CYRAMZA, IRRs occurred in 6 out of 37 patients (16%), including two severe events. The majority of IRRs across trials occurred during or following a first or second CYRAMZA infusion. Symptoms of IRRs included rigors/tremors, back pain/spasms, chest pain and/or tightness, chills, flushing, dyspnea, wheezing, hypoxia, and paresthesia. In severe cases, symptoms included bronchospasm, supraventricular tachycardia, and hypotension.
Monitor patients during the infusion for signs and symptoms of IRRs in a setting with available resuscitation equipment. Immediately and permanently discontinue CYRAMZA for Grade 3 or 4 IRRs [see Dosage and Administration (2.3)].
5.5 Gastrointestinal Perforations
CYRAMZA is an antiangiogenic therapy that can increase the risk of gastrointestinal perforation, a potentially fatal event. Four of 570 patients (0.7%) who received CYRAMZA as a single agent in clinical trials experienced gastrointestinal perforation. In Study 2, the incidence of gastrointestinal perforations was also increased in patients that received CYRAMZA plus paclitaxel (1.2%) as compared to patients receiving placebo plus paclitaxel (0.3%). In Study 3, the incidence of gastrointestinal perforation was 1% for CYRAMZA plus docetaxel and 0.3% for placebo plus docetaxel. Permanently discontinue CYRAMZA in patients who experience a gastrointestinal perforation [see Dosage and Administration (2.3)].
5.6 Impaired Wound Healing
CYRAMZA has not been studied in patients with serious or non-healing wounds. CYRAMZA is an antiangiogenic therapy with the potential to adversely affect wound healing.
Withhold CYRAMZA prior to surgery. Resume following the surgical intervention based on clinical judgment of adequate wound healing. If a patient develops wound healing complications during therapy, discontinue CYRAMZA until the wound is fully healed [see Dosage and Administration (2.3)].
5.7 Clinical Deterioration in Patients with Child-Pugh B or C Cirrhosis
Clinical deterioration, manifested by new onset or worsening encephalopathy, ascites, or hepatorenal syndrome was reported in patients with Child-Pugh B or C cirrhosis who received single-agent CYRAMZA. Use CYRAMZA in patients with Child-Pugh B or C cirrhosis only if the potential benefits of treatment are judged to outweigh the risks of clinical deterioration.
5.8 Reversible Posterior Leukoencephalopathy Syndrome
Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been reported with a rate of <0.1% in clinical studies with CYRAMZA. Confirm the diagnosis of RPLS with MRI and discontinue CYRAMZA in patients who develop RPLS. Symptoms may resolve or improve within days, although some patients with RPLS can experience ongoing neurologic sequelae or death.
6 ADVERSE REACTIONS
The following adverse drug reactions are discussed in greater detail in other sections of the label:
Hemorrhage [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)].
Arterial Thromboembolic Events [see Dosage and Administration (2.3) and Warnings and Precautions (5.2)].
Hypertension [see Dosage and Administration (2.3) and Warnings and Precautions (5.3)].
Infusion-Related Reactions [see Dosage and Administration (2.3) and Warnings and Precautions (5.4)].
Gastrointestinal Perforation [see Dosage and Administration (2.3) and Warnings and Precautions (5.5)].
Impaired Wound Healing [see Dosage and Administration (2.3) and Warnings and Precautions (5.6)].
Patients with Child-Pugh B or C Cirrhosis [see Warnings and Precautions (5.7)].
Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions (5.8)].
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Gastric Cancer
Safety data are presented from two randomized, placebo controlled clinical trials in which patients received CYRAMZA: Study 1, a randomized (2:1), double-blind, clinical trial in which 351 patients received either CYRAMZA 8 mg/kg intravenously every two weeks or placebo every two weeks and Study 2, a double-blind, randomized (1:1) clinical trial in which 656 patients received paclitaxel 80 mg/m2 on days 1, 8, and 15 of each 28-day cycle plus either CYRAMZA 8 mg/kg intravenously every two weeks or placebo every two weeks. Both trials excluded patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 or greater, uncontrolled hypertension, major surgery within 28 days, or patients receiving chronic anti-platelet therapy other than once daily aspirin. Study 1 excluded patients with bilirubin ≥1.5 mg/dL and Study 2 excluded patients with bilirubin >1.5 times the upper limit of normal.
CYRAMZA Administered as a Single Agent
Among 236 patients who received CYRAMZA (safety population) in Study 1, median age was 60 years, 28% were women, 76% were White, and 16% were Asian. Patients in Study 1 received a median of 4 doses of CYRAMZA; the median duration of exposure was 8 weeks, and 32 (14% of 236) patients received CYRAMZA for at least six months.
In Study 1, the most common adverse reactions (all grades) observed in CYRAMZA-treated patients at a rate of ≥10% and ≥2% higher than placebo were hypertension and diarrhea. The most common serious adverse events with CYRAMZA were anemia (3.8%) and intestinal obstruction (2.1%). Red blood cell transfusions were given to 11% of CYRAMZA-treated patients versus 8.7% of patients who received placebo.
Table 2 provides the frequency and severity of adverse reactions in Study 1.
Table 2: Adverse Reactions Occurring at Incidence Rate ≥5% and a ≥2% Difference Between Arms in Patients Receiving CYRAMZA in Study 1

Adverse Reactions (MedDRA)
System Organ Class
CYRAMZA (8 mg/kg)
N=236
Placebo
N=115
All Grades
(Frequency %)
Grade 3-4
(Frequency %)
All Grades
(Frequency %)
Grade 3-4
(Frequency %)
Gastrointestinal Disorders
     Diarrhea 14 1 9 2
Metabolism and Nutrition Disorders
     Hyponatremia 6 3 2 1
Nervous System Disorders
     Headache 9 0 3 0
Vascular Disorders
     Hypertension 16 8 8 3
Clinically relevant adverse reactions reported in ≥1% and <5% of CYRAMZA-treated patients in Study 1 were: neutropenia (4.7% CYRAMZA versus 0.9% placebo), epistaxis (4.7% CYRAMZA versus 0.9% placebo), rash (4.2% CYRAMZA versus 1.7% placebo), intestinal obstruction (2.1% CYRAMZA versus 0% placebo), and arterial thromboembolic events (1.7% CYRAMZA versus 0% placebo) [see Dosage and Administration (2.3) and Warnings and Precautions (5.1, 5.2)].
Across clinical trials of CYRAMZA administered as a single agent, clinically relevant adverse reactions (including Grade ≥3) reported in CYRAMZA-treated patients included proteinuria, gastrointestinal perforation, and infusion-related reactions.
In Study 1, according to laboratory assessment, 8% of CYRAMZA-treated patients developed proteinuria versus 3% of placebo-treated patients. Two patients discontinued CYRAMZA due to proteinuria. The rate of gastrointestinal perforation in Study 1 was 0.8% and the rate of infusion-related reactions was 0.4% [see Dosage and Administration (2.2, 2.3) and Warnings and Precautions (5.4, 5.5)].
CYRAMZA Administered in Combination with Paclitaxel
Among 327 patients who received CYRAMZA (safety population) in Study 2, median age was 60 years, 31% were women, 63% were White, and 33% were Asian. Patients in Study 2 received a median of 9 doses of CYRAMZA; the median duration of exposure was 18 weeks, and 93 (28% of 327) patients received CYRAMZA for at least six months.
In Study 2, the most common adverse reactions (all grades) observed in patients treated with CYRAMZA plus paclitaxel at a rate of ≥30% and ≥2% higher than placebo plus paclitaxel were fatigue, neutropenia, diarrhea, and epistaxis. The most common serious adverse events with CYRAMZA plus paclitaxel were neutropenia (3.7%) and febrile neutropenia (2.4%); 19% of patients treated with CYRAMZA plus paclitaxel received granulocyte colony-stimulating factors. Adverse reactions resulting in discontinuation of any component of the CYRAMZA plus paclitaxel combination in 2% or more patients in Study 2 were neutropenia (4%) and thrombocytopenia (3%).
Table 3 provides the frequency and severity of adverse reactions in Study 2.
Table 3: Adverse Reactions Occurring at Incidence Rate ≥5% and a ≥2% Difference Between Arms in Patients Receiving CYRAMZA plus Paclitaxel in Study 2 

Adverse Reactions (MedDRA) System Organ Class CYRAMZA plus Paclitaxel
(N=327)
Placebo plus Paclitaxel
(N=329)
All Grades
(Frequency %)
Grade ≥3 (Frequency %) All Grades
(Frequency %)
Grade ≥3 (Frequency %)
Blood and Lymphatic System Disorders
     Neutropenia 54 41 31 19
     Thrombocytopenia 13 2 6 2
Gastrointestinal Disorders
     Diarrhea 32 4 23 2
     Gastrointestinal hemorrhage events 10 4 6 2
     Stomatitis 20 1 7 1
General Disorders and Administration Site Disorders
     Fatigue/Asthenia 57 12 44 6
     Peripheral edema 25 2 14 1
Metabolism and Nutrition Disorders
     Hypoalbuminemia 11 1 5 1
Renal and Urinary Disorders
     Proteinuria 17 1 6 0
Respiratory, Thoracic, and Mediastinal Disorders
     Epistaxis 31 0 7 0
Vascular Disorder
     Hypertension 25 15 6 3
Clinically relevant adverse reactions reported in ≥1% and <5% of the CYRAMZA plus paclitaxel treated patients in Study 2 were sepsis (3.1% CYRAMZA plus paclitaxel versus 1.8% placebo plus paclitaxel) and gastrointestinal perforations (1.2% CYRAMZA plus paclitaxel versus 0.3% for placebo plus paclitaxel).
Non-Small Cell Lung Cancer
CYRAMZA Administered in Combination with Docetaxel
Study 3 was a multinational, randomized, double-blind study conducted in patients with NSCLC with disease progression on or after one platinum-based therapy for locally advanced or metastatic disease. Patients received either CYRAMZA 10 mg/kg intravenously plus docetaxel 75 mg/m2 intravenously every 3 weeks or placebo plus docetaxel 75 mg/m2 intravenously every 3 weeks. Due to an increased incidence of neutropenia and febrile neutropenia in patients enrolled in East Asian sites, Study 3 was amended and 24 patients (11 CYRAMZA plus docetaxel, 13 placebo plus docetaxel) at East Asian sites received a starting dose of docetaxel at 60 mg/m2 every 3 weeks.
Study 3 excluded patients with an ECOG PS of 2 or greater, bilirubin greater than the upper limit of normal (ULN), uncontrolled hypertension, major surgery within 28 days, radiographic evidence of major airway or blood vessel invasion by cancer, radiographic evidence of intra-tumor cavitation, or gross hemoptysis within the preceding 2 months, and patients receiving therapeutic anticoagulation or chronic anti-platelet therapy other than once daily aspirin. The study also excluded patients whose only prior treatment for advanced NSCLC was a tyrosine kinase (epidermal growth factor receptor [EGFR] or anaplastic lymphoma kinase [ALK]) inhibitor.
The data described below reflect exposure to CYRAMZA plus docetaxel in 627 patients in Study 3. Demographics and baseline characteristics were similar between treatment arms. Median age was 62 years; 67% of patients were men; 84% were White and 12% were Asian; 33% had ECOG PS 0; 74% had non-squamous histology and 25% had squamous histology. Patients received a median of 4.5 doses of CYRAMZA; the median duration of exposure was 3.5 months, and 195 (31% of 627) patients received CYRAMZA for at least six months.
In Study 3, the most common adverse reactions (all grades) observed in CYRAMZA plus docetaxel-treated patients at a rate of ≥30% and ≥2% higher than placebo plus docetaxel were neutropenia, fatigue/asthenia, and stomatitis/mucosal inflammation. Treatment discontinuation due to adverse reactions occurred more frequently in CYRAMZA plus docetaxel-treated patients (9%) than in placebo plus docetaxel-treated patients (5%). The most common adverse events leading to treatment discontinuation of CYRAMZA were infusion-related reaction (0.5%) and epistaxis (0.3%). For patients with non-squamous histology, the overall incidence of pulmonary hemorrhage was 7% and the incidence of ≥Grade 3 pulmonary hemorrhage was 1% for CYRAMZA plus docetaxel compared to 6% overall incidence and 1% for ≥Grade 3 pulmonary hemorrhage for placebo plus docetaxel. For patients with squamous histology, the overall incidence of pulmonary hemorrhage was 10% and the incidence of ≥Grade 3 pulmonary hemorrhage was 2% for CYRAMZA plus docetaxel compared to 12% overall incidence and 2% for ≥Grade 3 pulmonary hemorrhage for placebo plus docetaxel.
The most common serious adverse events with CYRAMZA plus docetaxel were febrile neutropenia (14%), pneumonia (6%), and neutropenia (5%). The use of granulocyte colony-stimulating factors was 42% in CYRAMZA plus docetaxel-treated patients versus 37% in patients who received placebo plus docetaxel. In patients ≥65 years, there were 18 (8%) deaths on treatment or within 30 days of discontinuation for CYRAMZA plus docetaxel and 9 (4%) deaths for placebo plus docetaxel. In patients <65 years, there were 13 (3%) deaths on treatment or within 30 days of discontinuation for CYRAMZA plus docetaxel and 26 (6%) deaths for placebo plus docetaxel.
Table 4 provides the frequency and severity of adverse reactions in Study 3.
Table 4: Adverse Reactions Occurring at Incidence Rate ≥5% and a ≥2% Difference Between Arms in Patients Receiving CYRAMZA in Study 3 

Adverse Reactions (MedDRA)
System Organ Class
CYRAMZA plus docetaxel
(N=627)
Placebo plus docetaxel
(N=618)
All Grades
(Frequency %)
Grade 3-4
(Frequency %)
All Grades
(Frequency %)
Grade 3-4
(Frequency %)
Blood and Lymphatic System Disorders
       Febrile neutropenia 16 16 10 10
       Neutropenia 55 49 46 40
       Thrombocytopenia 13 3 5 <1
Gastrointestinal Disorders
       Stomatitis/Mucosal inflammation 37 7 19 2
Eye Disorders
       Lacrimation increased 13 <1 5 0
General Disorders and Administration Site Disorders
       Fatigue/Asthenia 55 14 50 11
       Peripheral edema 16 0 9 <1
Respiratory, Thoracic, and Mediastinal Disorders
       Epistaxis 19 <1 7 <1
Vascular Disorders
       Hypertension 11 6 5 2
Clinically relevant adverse drug reactions reported in ≥1% and <5% of the CYRAMZA plus docetaxel-treated patients in Study 3 were hyponatremia (4.8% CYRAMZA plus docetaxel versus 2.4% for placebo plus docetaxel) and proteinuria (3.3% CYRAMZA plus docetaxel versus 0.8% placebo plus docetaxel).
6.2 Immunogenicity
As with all therapeutic proteins, there is the potential for immunogenicity. In 19 clinical trials, 70/2131 (3.3%) of CYRAMZA-treated patients with post baseline serum samples tested positive for treatment-emergent anti-ramucirumab antibodies by an enzyme-linked immunosorbent assay (ELISA). Neutralizing antibodies were detected in 12 of the 70 patients who tested positive for treatment-emergent anti-ramucirumab antibodies.
The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to CYRAMZA with the incidences of antibodies to other products may be misleading.
7 DRUG INTERACTIONS
No pharmacokinetic (PK) interactions were observed between ramucirumab and paclitaxel or between ramucirumab and docetaxel [see Clinical Pharmacology (12.3)].
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Category C
Risk Summary
Based on its mechanism of action, CYRAMZA may cause fetal harm. Animal models link angiogenesis, VEGF and VEGF Receptor 2 (VEGFR2) to critical aspects of female reproduction, embryofetal development, and postnatal development. There are no adequate or well controlled studies of ramucirumab in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus.
Animal Data
No animal studies have been specifically conducted to evaluate the effect of ramucirumab on reproduction and fetal development. In mice, loss of the VEGFR2 gene resulted in embryofetal death and these fetuses lacked organized blood vessels and blood islands in the yolk sac. In other models, VEGFR2 signaling was associated with development and maintenance of endometrial and placental vascular function, successful blastocyst implantation, maternal and feto-placental vascular differentiation, and development during early pregnancy in rodents and non-human primates. Disruption of VEGF signaling has also been associated with developmental anomalies including poor development of the cranial region, forelimbs, forebrain, heart, and blood vessels.
8.3 Nursing Mothers
It is not known whether CYRAMZA is excreted in human milk. No studies have been conducted to assess CYRAMZA's impact on milk production or its presence in breast milk. Human IgG is excreted in human milk, but published data suggests that breast milk antibodies do not enter the neonatal and infant circulation in substantial amounts. Because many drugs are excreted in human milk and because of the potential risk for serious adverse reactions in nursing infants from ramucirumab, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
8.4 Pediatric Use
The safety and effectiveness of CYRAMZA in pediatric patients have not been established. In animal studies, effects on epiphyseal growth plates were identified. In cynomolgus monkeys, anatomical pathology revealed adverse effects on the epiphyseal growth plate (thickening and osteochondropathy) at all doses tested (5-50 mg/kg). Ramucirumab exposure at the lowest weekly dose tested in the cynomolgus monkey was 0.2 times the exposure in humans at the recommended dose of ramucirumab as a single agent.
8.5 Geriatric Use
Of the 563 CYRAMZA-treated patients in two randomized gastric cancer clinical studies, 36% were 65 and over, while 7% were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. [see Clinical Studies (14.1)]
Of the 1253 patients in Study 3, 455 (36%) were 65 and over and 84 (7%) were 75 and over. Of the 627 patients who received CYRAMZA plus docetaxel in Study 3, 237 (38%) were 65 and over, while 45 (7%) were 75 and over [see Clinical Studies (14.2)]. In an exploratory subgroup analysis of Study 3, the hazard ratio for overall survival in patients less than 65 years old was 0.74 (95% CI: 0.62, 0.87) and in patients 65 years or older was 1.10 (95% CI: 0.89, 1.36). [see Clinical Studies (14.2)]
8.6 Renal Impairment
No dose adjustment is recommended for patients with renal impairment based on population PK analysis [see Clinical Pharmacology (12.3)].
8.7 Hepatic Impairment
No dose adjustment is recommended for patients with mild hepatic impairment (total bilirubin within upper limit of normal [ULN] and aspartate aminotransferase [AST] >ULN or total bilirubin >1.0-1.5 times ULN and any AST) based on population PK analysis. Clinical deterioration was reported in patients with Child-Pugh B or C cirrhosis who received single-agent CYRAMZA [see Warnings and Precautions (5.7) and Clinical Pharmacology (12.3)].
8.8 Females and Males of Reproductive Potential
Fertility
Advise females of reproductive potential that CYRAMZA may impair fertility [see Nonclinical Toxicology (13.1)].
Contraception
Based on its mechanism of action, CYRAMZA may cause fetal harm [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to avoid getting pregnant while receiving CYRAMZA and for at least 3 months after the last dose of CYRAMZA.
10 OVERDOSAGE
There are no data on overdose in humans. CYRAMZA was administered at doses up to 10 mg/kg every two weeks without reaching a maximum tolerated dose.
11 DESCRIPTION
CYRAMZA (ramucirumab) is a recombinant human IgG1 monoclonal antibody that specifically binds to vascular endothelial growth factor receptor 2. CYRAMZA has an approximate molecular weight of 147 kDa. CYRAMZA is produced in genetically engineered mammalian NS0 cells.
CYRAMZA is a sterile, preservative-free, clear to slightly opalescent and colorless to slightly yellow solution for intravenous infusion following dilution and preparation. CYRAMZA is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-dose vials. CYRAMZA is formulated in glycine (9.98 mg/mL), histidine (0.65 mg/mL), histidine monohydrochloride (1.22 mg/mL), polysorbate 80 (0.1 mg/mL), sodium chloride (4.383 mg/mL), and Water for Injection, USP, pH 6.0.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Ramucirumab is a vascular endothelial growth factor receptor 2 antagonist that specifically binds VEGF Receptor 2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand-stimulated activation of VEGF Receptor 2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.
12.3 Pharmacokinetics
With the dosing regimen of 8 mg/kg every 2 weeks in patients with advanced gastric or gastro-esophageal junction cancer, the geometric means of the minimum ramucirumab concentrations (Cmin) were 50 μg/mL (6-228 μg/mL) after the third dose and 74 μg/mL (14-234 μg/mL) after the sixth dose. Similar Cmin values of ramucirumab were observed when ramucirumab was administered with paclitaxel. Based on a population PK analysis, the mean (% coefficient of variation [CV%]) volume of distribution at steady state for ramucirumab was 5.5 L (14%), the mean clearance was 0.014 L/hour (30%), and the mean elimination half-life was 15 days (24%).
With the dosing regimen of 10 mg/kg every 21 days in patients with NSCLC, the geometric means (ranges) of the minimum ramucirumab concentrations (Cmin) were 28 μg/mL (3-108 μg/mL) after the second dose and 38 μg/mL (3-128 μg/mL) after the fourth dose. Based on a population PK analysis in NSCLC patients, the mean (% coefficient of variation [CV%]) clearance for ramucirumab was 0.015 L/hour (27%), the mean volume of distribution at steady state (Vss) was 7.1 L (13%), and the mean elimination half-life was 23 days (24%).
Specific Populations
Age, sex, and race had no clinically meaningful effect on the PK of ramucirumab based on a population PK analysis.
Renal Impairment: The effect of renal impairment on the average concentration of ramucirumab at steady state (Css) was evaluated in patients with mild (calculated creatinine clearance [CLcr] 60-89 mL/min, n=368), moderate (CLcr 30-59 mL/min, n=160) or severe (CLcr 15 -29 mL/min, n=4) renal impairment compared to patients with normal renal function (CLcr ≥90 mL/min, n=360) in a population PK analysis. No clinically meaningful differences in the average Css of ramucirumab were observed between patients with renal impairment and patients with normal renal function.
Hepatic Impairment: The effect of hepatic impairment on the average Css of ramucirumab was evaluated in patients with mild (total bilirubin within upper limit of normal [ULN] and AST>ULN or total bilirubin >1.0-1.5 times ULN and any AST, n=143) compared to patients with normal hepatic function (total bilirubin and AST ≤ULN, n=735) in a population PK analysis. No clinically meaningful differences in the average Css of ramucirumab were found between patients with mild hepatic impairment and patients with normal hepatic function. No PK data were available from patients with moderate (total bilirubin >1.5-3.0 times ULN and any AST) or severe hepatic dysfunction (total bilirubin >3.0 times ULN and any AST).
Drug Interaction Studies
No clinically meaningful changes in paclitaxel exposure or ramucirumab exposure were observed when CYRAMZA 8 mg/kg and paclitaxel 80 mg/m2 were co-administered in patients with solid tumors.
No clinically meaningful changes in docetaxel exposure were observed when CYRAMZA 10 mg/kg and docetaxel 75 mg/m2 were co-administered in patients with solid tumors. Ramucirumab exposure appeared to be comparable regardless of concomitant docetaxel based on cross study comparisons in patients with solid tumors.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
No animal studies have been performed to test ramucirumab for potential carcinogenicity or genotoxicity.
Inhibition of VEGFR2 signaling in animal models was shown to result in changes to hormone levels critical for pregnancy, and, in monkeys, an increased duration of the follicular cycle. In a 39 week animal study, female monkeys treated with ramucirumab showed dose dependent increases in follicular mineralization of the ovary.
13.2 Animal Toxicology and/or Pharmacology
Adverse effects in the kidney (glomerulonephritis) occurred with doses of 16-50 mg/kg (0.7-5.5 times the exposure in humans at the recommended dose of ramucirumab as a single agent).
A single dose of ramucirumab resulting in an exposure approximately 10 times the exposure in humans at the recommended dose of ramucirumab as a single agent did not significantly impair wound healing in monkeys using a full-thickness incisional model.
14 CLINICAL STUDIES
14.1 Gastric Cancer
Study 1 was a multinational, randomized, double-blind, multicenter study of CYRAMZA plus best supportive care (BSC) versus placebo plus BSC that randomized (2:1) 355 patients with locally advanced or metastatic gastric cancer (including adenocarcinoma of the gastro-esophageal junction [GEJ]) who previously received platinum- or fluoropyrimidine-containing chemotherapy. The major efficacy outcome measure was overall survival and the supportive efficacy outcome measure was progression-free survival. Patients were required to have experienced disease progression either within 4 months after the last dose of first-line therapy for locally advanced or metastatic disease or within 6 months after the last dose of adjuvant therapy. Patients were also required to have ECOG PS of 0 or 1. Patients received either an intravenous infusion of CYRAMZA 8 mg/kg (n=238) or placebo solution (n=117) every 2 weeks. Randomization was stratified by weight loss over the prior 3 months (≥10% versus <10%), geographic region, and location of the primary tumor (gastric versus GEJ).
Demographic and baseline characteristics were similar between treatment arms. Median age was 60 years; 70% of patients were men; 77% were White, 16% Asian; the ECOG PS was 0 for 28% of patients and 1 for 72% of patients; 91% of patients had measurable disease; 75% of patients had gastric cancer; and 25% had adenocarcinoma of the GEJ. The majority of patients (85%) experienced disease progression during or following first-line therapy for metastatic disease. Prior chemotherapy for gastric cancer consisted of platinum/fluoropyrimidine combination therapy (81%), fluoropyrimidine-containing regimens without platinum (15%), and platinum-containing regimens without fluoropyrimidine (4%). In Study 1, patients received a median of 4 doses (range 1-34) of CYRAMZA or a median of 3 doses (range 1-30) of placebo.
Overall survival and progression-free survival were statistically significantly improved in patients randomized to receive CYRAMZA as compared to patients randomized to receive placebo. Efficacy results are shown in Table 5 and Figure 1.
Table 5: Randomized Trial of CYRAMZA plus BSC versus Placebo plus BSC in Gastric Cancer 

CYRAMZA
N=238
Placebo
N=117
Overall Survival
     Number of deaths (%) 179 (75%) 99 (85%)
     Median – months (95% CI) 5.2 (4.4, 5.7) 3.8 (2.8, 4.7)
     Hazard Ratio (95% CI) 0.78 (0.60, 0.998)
     Stratified Log-rank p-value 0.047
Progression-free Survival
     Number of events (%) 199 (84%) 108 (92%)
     Median – months (95% CI) 2.1 (1.5, 2.7) 1.3 (1.3, 1.4)
     Hazard Ratio (95% CI) 0.48 (0.38, 0.62)
     Stratified Log-rank p-value <0.001
Abbreviations: CI = confidence interval
Figure 1: Kaplan-Meier Curves of Overall Survival - CYRAMZA plus BSC versus Placebo plus BSC in Gastric Cancer


Study 2 was a multinational, randomized, double-blind study of CYRAMZA plus paclitaxel versus placebo plus paclitaxel that randomized (1:1) 665 patients with locally advanced or metastatic gastric cancer (including adenocarcinoma of the gastro-esophageal junction) who previously received platinum- and fluoropyrimidine-containing chemotherapy. Patients were required to have experienced disease progression during, or within 4 months after the last dose of first-line therapy. Patients were also required to have ECOG PS of 0 or 1. Randomization was stratified by geographic region, time to progression from the start of first-line therapy (<6 months versus ≥6 months) and disease measurability.
Patients were randomized to receive either CYRAMZA 8 mg/kg (n=330) or placebo (n=335) as an intravenous infusion every 2 weeks (on days 1 and 15) of each 28-day cycle. Patients in both arms received paclitaxel 80 mg/m2 by intravenous infusion on days 1, 8, and 15 of each 28-day cycle. Prior to administration of each dose of paclitaxel, patients were required to have adequate hematopoietic and hepatic function. The paclitaxel dose was permanently reduced in increments of 10 mg/m2 for a maximum of two dose reductions for Grade 4 hematologic toxicity or Grade 3 paclitaxel-related non-hematologic toxicity. The major efficacy outcome measure was overall survival and the supportive efficacy outcome measures were progression-free survival and objective response rate.
Demographics and baseline characteristics were similar between treatment arms including the following: Median age was 61 years; 71% of patients were men; 61% were White, 35% Asian; the ECOG PS was 0 for 39% of patients, 1 for 61% of patients; 78% of patients had measurable disease; 79% of patients had gastric cancer; and 21% had adenocarcinoma of the GEJ. Two-thirds of the patients experienced disease progression while on first-line therapy (67%) and 25% of patients received an anthracycline in combination with platinum/fluoropyrimidine combination therapy.
Overall survival, progression-free survival, and objective response rate were statistically significantly improved in patients randomized to receive CYRAMZA plus paclitaxel compared to patients randomized to receive placebo plus paclitaxel. Efficacy results are shown in Table 6 and Figure 2.
Table 6: Randomized Trial of CYRAMZA plus Paclitaxel versus Placebo plus Paclitaxel in Gastric Cancer 

CYRAMZA + paclitaxel
N=330
Placebo + paclitaxel
N=335
Overall Survival
     Number of deaths (%) 256 (78%) 260 (78%)
     Median – months (95% CI) 9.6 (8.5, 10.8) 7.4 (6.3, 8.4)
     Hazard Ratio (95% CI) 0.81 (0.68, 0.96)
     Stratified Log-rank p-value 0.017
Progression-free Survival
     Number of events (%) 279 (85%) 296 (88%)
     Median – months (95% CI) 4.4 (4.2, 5.3) 2.9 (2.8, 3.0)
     Hazard Ratio (95% CI) 0.64 (0.54, 0.75)
     Stratified Log-rank p-value <0.001
Objective Response Rate (CR + PR)
     Rate – percent (95% CI) 28 (23, 33) 16 (13, 20)
     Stratified CMH p-value <0.001
Abbreviations: CI = confidence interval, CR = complete response, PR = partial response, CMH = Cochran-Mantel-Haenszel
Figure 2: Kaplan-Meier Curves of Overall Survival - CYRAMZA plus Paclitaxel versus Placebo plus Paclitaxel in Gastric Cancer


14.2 Non-Small Cell Lung Cancer
Study 3 was a multinational, randomized, double-blind, study of CYRAMZA plus docetaxel versus placebo plus docetaxel, that randomized (1:1) 1253 patients with NSCLC with disease progression on or after one platinum-based therapy for locally advanced or metastatic disease. The major efficacy outcome measure was overall survival and the supportive efficacy outcome measures were progression-free survival and objective response rate. Patients were also required to have ECOG PS 0 or 1. Patients were randomized to receive either CYRAMZA at 10 mg/kg or placebo by intravenous infusion, in combination with docetaxel at 75 mg/m2 every 21 days. Sites in East Asia administered a reduced dose of docetaxel at 60 mg/m2 every 21 days. Patients who discontinued combination therapy because of an adverse event attributed to either CYRAMZA/placebo or docetaxel were permitted to continue monotherapy with the other treatment component until disease progression or intolerable toxicity. Randomization was stratified by geographic region, gender, prior maintenance therapy, and ECOG PS.
Demographics and baseline characteristics were similar between treatment arms. Median age was 62 years; 67% of patients were men; 82% were White and 13% were Asian; 32% had ECOG PS 0; 73% had nonsquamous histology and 26% had squamous histology. In addition to platinum chemotherapy (99%), the most common prior therapies were pemetrexed (38%), gemcitabine (25%), taxane (24%), and bevacizumab (14%). Twenty-two percent of patients received prior maintenance therapy. Tumor EGFR status was unknown for the majority of patients (65%). Where tumor EGFR status was known (n=445), 7.5% were positive for EGFR mutation (n=33). No data were collected regarding tumor ALK rearrangement status.
Overall survival and progression-free survival were statistically significantly improved in patients randomized to receive CYRAMZA plus docetaxel compared to patients randomized to receive placebo plus docetaxel. Objective response rate (complete response + partial response) was 23% (95% CI: 20, 26) for CYRAMZA plus docetaxel and 14% (95% CI: 11, 17) for placebo plus docetaxel, p-value of <0.001. Efficacy results are shown in Table 7 and Figure 3.
Table 7: Randomized Trial of CYRAMZA plus Docetaxel versus Placebo plus Docetaxel in NSCLC

CYRAMZA + docetaxel
N=628
Placebo + docetaxel
N=625
Overall Survival
       Number of deaths (%) 428 (68%) 456 (73%)
       Median – months (95% CI) 10.5 (9.5, 11.2) 9.1 (8.4, 10.0)
       Hazard Ratio (95% CI) 0.86 (0.75, 0.98)
       Stratified Log-rank p-value 0.024
Progression-free Survival
       Number of events (%) 558 (89%) 583 (93%)
       Median – months (95% CI) 4.5 (4.2, 5.4) 3.0 (2.8, 3.9)
       Hazard Ratio (95% CI) 0.76 (0.68, 0.86)
       Stratified Log-rank p-value <0.001
Abbreviations: CI = confidence interval
Figure 3: Kaplan-Meier Curves of Overall Survival - CYRAMZA plus Docetaxel versus Placebo plus Docetaxel in NSCLC


16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
CYRAMZA is supplied in single-dose vials as a sterile, preservative-free solution.
NDC 0002-7669-01
100 mg/10 mL (10 mg/mL), individually packaged in a carton
NDC 0002-7678-01
500 mg/50 mL (10 mg/mL), individually packaged in a carton
16.2 Storage and Handling Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) until time of use. Keep the vial in the outer carton in order to protect from light. DO NOT FREEZE OR SHAKE the vial.
--------------------------------------------
产地国家: 美国
原产地英文商品名:
CYRAMZA 100mg/10ml 3 vials
原产地英文药品名:
RAMUCIRUMAB
中文参考商品译名:
CYRAMZA注射液 100毫克/10毫升 3瓶
中文参考药品译名:
雷莫芦单抗
生产厂家中文参考译名:
礼来
生产厂家英文名:
ELI LILLY AND CO
--------------------------------------------
产地国家: 美国
原产地英文商品名:
CYRAMZA 500mg/10ml 3 vials
原产地英文药品名:
RAMUCIRUMAB
中文参考商品译名:
CYRAMZA注射液 500毫克/10毫升 3瓶
中文参考药品译名:
雷莫芦单抗
生产厂家中文参考译名:
礼来
生产厂家英文名:
ELI LILLY AND CO

责任编辑:admin


相关文章
多发性骨髓瘤新药Farydak(Panobinostat)获欧盟批准
达卡他韦片|Daklinza(Daclatasvir Tablets)
Daklinza(Daclatasvir Tablets)
Daklinza Tablets(Daclatasvir Hydrochloride)
Technivie(ombitasvir,paritaprevir和利托那韦 ritonavir)复方片
Daklinza tablets(daclatasvir film-coated)
Daklinza(daclatasvir)临床治疗基因型3慢性丙型肝炎
奥利万星注射液Orbactiv(oritavancin)
ENTRESTO tablets(奥帕曲拉/缬沙坦复方片)
ENTRESTO(sacubitril and valsartan)tablets
美国FDA批准Entresto为治疗心力衰竭新药
 

最新文章

更多

· Alecensa Capsule(Alect...
· 克里唑蒂尼胶囊|Xalkori...
· KEYTRUDA(pembrolizumab...
· Vargatef(nintedanibsof...
· OPDIVO(nivolumab)injection
· Vargatef(nintedanib s...
· 雷莫芦单抗注射剂|CYRAM...
· TARCEVA(Erlotinib Hyd...
· Gilotrif tab(Afatinib...
· ELPLAT I. V. INFUSION ...

推荐文章

更多

· Alecensa Capsule(Alect...
· 克里唑蒂尼胶囊|Xalkori...
· KEYTRUDA(pembrolizumab...
· Vargatef(nintedanibsof...
· OPDIVO(nivolumab)injection
· Vargatef(nintedanib s...
· 雷莫芦单抗注射剂|CYRAM...
· TARCEVA(Erlotinib Hyd...
· Gilotrif tab(Afatinib...
· ELPLAT I. V. INFUSION ...

热点文章

更多

· Alecensa Capsule(Alect...